75% of US-Based Operation Warp Speed Vaccine Trials Overseen by Advarra IRB, IBC
Webinar: October 27
Trust Advarra’s integrated solutions and collaborative approach to make your research altogether better.
Advarra® provides institutional review board (IRB), institutional biosafety committee (IBC) and GxP/HRP research compliance consulting services with unprecedented clarity.
Advarra recently acquired Forte, the market-leading provider of clinical technology solutions including OnCore. Learn more
Our Latest Updates
Discover What’s Happening at Advarra
Advarra Joins #NoGoingBack Movement to Preserve Recent Progress in Clinical Research
Signant Health recently initiated the #NoGoingBack movement, recognizing that COVID-19 forced the clinical research community to move trial conduct forward rapidly. This movement focuses on keeping in place the clinical…
Racial Diversity in Clinical Trials: Building Trust in Participant Engagement
COVID-19 has focused the importance of diversity, equity, and inclusion considerations in clinical trial enrollment. How can the research community address the root causes for lack of diversity? What actions…
Q&A – The Must-Haves of FDA and Common Rule Reporting Requirements
In a recent webinar, Advarra regulatory experts discussed the must-haves of FDA and Common Rule reporting requirements. They reviewed the basics of what must be reported to whom—and when—for sponsors…
Society of Research Administrators International (SRA International)
October 17-21, 2020
Virtual